400 Professional Drive
About Emergent BioSolutions
Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through our specialty products and contract development and manufacturing services, we are dedicated to providing solutions that address public health threats. Through social responsibility, we aim to build healthier and safer communities. We aspire to deliver peace of mind to our patients and customers so they can focus on what’s most important in their lives. In working together, we envision protecting or enhancing 1 billion lives by 2030. For more information visit www.emergentbiosolutions.com. Find us on LinkedIn and follow us on Twitter.
Stock Symbol: EBS
532 articles with Emergent BioSolutions
Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second quarter ended June 30, 2022.
WHO declared the monkeypox outbreak a “public health emergency of international concern [PHEIC].” As COVID-19 wanes, Tonix, SIGA, Emergent Bio and others are now targeting monkeypox.
Emergent BioSolutions to Release Second Quarter 2022 Financial Results and Conduct Conference Call on August 1, 2022
Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Monday, August 1, 2022, at 5:00 pm eastern time to discuss the financial results for the second quarter of 2022, recent business developments, revenue guidance for the third quarter of 2022, and financial outlook for full year 2022.
The latest employment report from the Bureau of Labor Statistics shows that employment for healthcare workers is returning to pre-pandemic levels, and biopharma employers appear to be in equally good shape.
Emergent BioSolutions and Ridgeback Biotherapeutics Enter Into Agreement for Ebanga™ Treatment for Ebola
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement with Ridgeback Biotherapeutics (“Ridgeback Bio”), a biotechnology company focused on emerging infectious diseases, intended to create a collaboration to expand the availability of Ebanga™ (Ansuvimab-zykl).
Emergent BioSolutions Inc. announced that the company’s board of directors appointed Sujata Dayal as a Class II director to serve on the board effective July 15, 2022, with an initial term expiring at the 2023 annual meeting of stockholders.
With the submission of NDAs and BLAs, multiple companies are bidding for regulatory approval of drug candidates. BioSpace takes a look at several of the latest requests.
Emergent BioSolutions Announces FDA Acceptance of Biologics License Application for AV7909 Anthrax Vaccine Candidate
Emergent BioSolutions Inc. announced that the U.S. Food and Drug Administration accepted for review the Biologics License Application for AV7909.
The week began with positive updates in the vaccine development space against various infectious diseases from Emergent, Merck, Affinivax and Ocugen.
Emergent BioSolutions Announces Publication of CHIKV VLP Phase 2 Safety and Immunogenicity Data in The Lancet Infectious Diseases
Emergent BioSolutions Inc. announced that two-year persistence data from its phase 2 clinical study evaluating the safety and immunogenicity of the company’s investigational chikungunya virus virus-like particle vaccine candidate were published in The Lancet Infectious Diseases.
Johnson & Johnson and Emergent BioSolutions are accusing each other of breaching their COVID-19 vaccine supply agreement.
Emergent BioSolutions Inc. announced that members of the company’s executive management team will participate in the following investor conferences.
Emergent BioSolutions to Acquire from Chimerix its Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages
Emergent BioSolutions Inc. announced that it has entered into a definitive agreement with Chimerix, Inc., to acquire Chimerix’s exclusive worldwide rights to TEMBEXA®, the first antiviral approved by the U.S. Food and Drug Administration for all age groups for the treatment of smallpox.
Chimerix announces it has entered into a definitive agreement with Emergent BioSolutions Inc. to acquire its exclusive worldwide rights to brincidofovir, including TEMBEXA®.
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 26, 2022 at 9:00am EDT
Emergent BioSolutions Inc. announced that its 2022 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on Thursday, May 26, 2022 at 9:00 AM EDT.
An investigation conducted by the U.S. House of Representatives shows Emergent was forced to destroy nearly 400 million doses of the vaccine. The company disputes the report’s claim.
Emergent BioSolutions Founder and former chief executive officer Fuad El-Hibri has died, the company reported.
“Emergent remains focused on our strategic plan to grow within public health threat markets where we can positively impact patients and customers,” said Robert G. Kramer, president and CEO of Emergent BioSolutions.
Emergent BioSolutions to Release First Quarter 2022 Financial Results and Conduct Conference Call on April 28, 2022
Emergent BioSolutions Inc. will host a conference call on Thursday, April 28, 2022, at 5:00 pm eastern time to discuss the financial results for the first quarter of 2022, recent business developments, revenue guidance for the second quarter of 2022, and financial outlook for full year 2022.
Emergent BioSolutions Inc. announced that its board of directors has undertaken a series of changes consistent with its commitment to continuous improvement of best practices for corporate governance.